 Acasti Pharma NASDAQ: ACST shares are trading higher on Monday after B.Riley FBR upgraded the stock from Neutral to Buy and announced a price target of 2 per share.Acasti Pharma is a biopharmaceutical innovator advancing a cardiovascular drug, CaPre omega-3 phospholipid, for the treatment of hypertriglyceridemia, a chronic condition affecting an estimated one third of the U.S. population. The company is focused on addressing a critical market need for an effective, safe and well-absorbing omega-3 therapeutic that can make a positive impact on the blood lipids associated with cardiovascular disease risk.The company is developing CaPre in a Phase 3 clinical program in patients with severe hypertriglyceridemiaAcasti Pharma shares were trading up 16.74 at 62 cents on Monday. The stock has a 52-week high of 3.08 and a 52-week low of 25 cents.Latest Ratings for ACST DateFirmActionFromTo Jul 2020B. Riley FBRUpgradesNeutralBuy May 2020Aegis CapitalMaintainsBuy Feb 2020H.C. WainwrightMaintainsBuy View More Analyst Ratings for ACST View the Latest Analyst RatingsSee more from Benzinga Dominion Energy Analyst Says Its An ESG Contender, Stays Sidelined Following Berkshire Deal Why Harley-Davidsons Stock Is Trading Higher Today Why Criteos Stock Is Trading Higher TodayC 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. 